Based on the key indicators related to China SXT's liquidity, profitability, solvency, and operating efficiency, China SXT Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December. At present, China SXT's Total Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 19.8 M, whereas Total Assets are forecasted to decline to about 21.9 M. Key indicators impacting China SXT's financial strength include:
The essential information of the day-to-day investment outlook for China SXT includes many different criteria found on its balance sheet. An individual investor should monitor China SXT's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in China SXT.
Net Income
(3.25 Million)
China
Select Account or Indicator
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Net Borrowings
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Investments
Stock Based Compensation
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Net Receivables
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Short Long Term Debt Total
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Non Current Assets Total
Non Currrent Assets Other
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Property Plant And Equipment Gross
Short Long Term Debt
Accumulated Other Comprehensive Income
Other Assets
Net Invested Capital
Net Working Capital
Capital Stock
Long Term Debt
Tax Provision
Interest Income
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Operating Income
Net Income From Continuing Ops
Ebit
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Interest Income
Depreciation And Amortization
Selling And Marketing Expenses
Other Operating Expenses
Ebitda
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past China SXT Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of China SXT's financial statements are interrelated, with each one affecting the others. For example, an increase in China SXT's assets may result in an increase in income on the income statement.
Please note, the presentation of China SXT's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, China SXT's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of China SXT's management manipulating its earnings.
China SXT Stock Summary
China SXT competes with Akanda Corp, Petros Pharmaceuticals, Shuttle Pharmaceuticals, Painreform, and Regencell Bioscience. China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets in China. The company was founded in 2005 and is headquartered in Taizhou, China. China Sxt operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 88 people.
Specialization
Consumer Staples, Drug Manufacturers - Specialty & Generic
Comparative valuation techniques use various fundamental indicators to help in determining China SXT's current stock value. Our valuation model uses many indicators to compare China SXT value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across China SXT competition to find correlations between indicators driving China SXT's intrinsic value. More Info.
China SXT Pharmaceuticals is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . At present, China SXT's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the China SXT's earnings, one of the primary drivers of an investment's value.
China SXT Pharmaceuticals Systematic Risk
China SXT's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. China SXT volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on China SXT Pharmaceuticals correlated with the market. If Beta is less than 0 China SXT generally moves in the opposite direction as compared to the market. If China SXT Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one China SXT Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of China SXT is generally in the same direction as the market. If Beta > 1 China SXT moves generally in the same direction as, but more than the movement of the benchmark.
About China SXT Financials
What exactly are China SXT Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include China SXT's income statement, its balance sheet, and the statement of cash flows. Potential China SXT investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although China SXT investors may use each financial statement separately, they are all related. The changes in China SXT's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on China SXT's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
Today, most investors in China SXT Stock are looking for potential investment opportunities by analyzing not only static indicators but also various China SXT's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of China SXT growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.005259
At present, China SXT's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
China SXT November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of China SXT help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of China SXT Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of China SXT Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing China Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build China SXT's daily price indicators and compare them against related drivers.
When running China SXT's price analysis, check to measure China SXT's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy China SXT is operating at the current time. Most of China SXT's value examination focuses on studying past and present price action to predict the probability of China SXT's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move China SXT's price. Additionally, you may evaluate how the addition of China SXT to your portfolios can decrease your overall portfolio volatility.